Verrica Pharmaceuticals Q3 Earnings Call Highlights

ملخص مفصل

Verrica Pharmaceuticals (NASDAQ:VRCA) reported record quarterly U.S. revenue for its molluscum treatment YCANTH in the third quarter of 2026, even as total revenue fell from a year earlier and its net loss widened. The company also outlined plans to explore its experimental drug VP-315 in patients